Avadel Pharmaceuticals plc (AVDL)
USD 7.73
(0.65%)
USD 7.73
(0.65%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 27.11 Million USD | 1797.99% |
| 2022 | -1.49 Million USD | -83.19% |
| 2021 | -815 Thousand USD | -104.91% |
| 2020 | 16.59 Million USD | -64.77% |
| 2019 | 47.09 Million USD | -45.09% |
| 2018 | 85.75 Million USD | -45.18% |
| 2017 | 156.44 Million USD | 14.19% |
| 2016 | 136.99 Million USD | -15.58% |
| 2015 | 162.28 Million USD | 1324.58% |
| 2014 | 11.39 Million USD | -37.04% |
| 2013 | 18.09 Million USD | -10.61% |
| 2012 | 20.24 Million USD | -23.08% |
| 2011 | 26.31 Million USD | -12.8% |
| 2010 | 30.18 Million USD | -5.69% |
| 2009 | 32 Million USD | 10.35% |
| 2008 | 28.99 Million USD | 49.98% |
| 2007 | 19.33 Million USD | 15.29% |
| 2006 | 16.77 Million USD | -20.42% |
| 2005 | 21.07 Million USD | -59.32% |
| 2004 | 51.8 Million USD | 141.07% |
| 2003 | 21.49 Million USD | 34.04% |
| 2002 | 16.03 Million USD | 46.81% |
| 2001 | 10.92 Million USD | 19.33% |
| 2000 | 9.15 Million USD | 2.22% |
| 1999 | 8.95 Million USD | 49.49% |
| 1998 | 5.98 Million USD | 19.78% |
| 1997 | 5 Million USD | 11.11% |
| 1996 | 4.5 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 25.65 Million USD | 36.76% |
| 2024 Q2 | 38.71 Million USD | 50.9% |
| 2023 Q2 | 1.46 Million USD | 348.3% |
| 2023 Q1 | -588 Thousand USD | -0.34% |
| 2023 FY | 25.35 Million USD | 1797.99% |
| 2023 Q3 | 6.89 Million USD | 372.4% |
| 2023 Q4 | 18.76 Million USD | 172.0% |
| 2022 Q4 | -586 Thousand USD | -46.13% |
| 2022 Q2 | -247 Thousand USD | 4.63% |
| 2022 FY | -1.49 Million USD | -83.19% |
| 2022 Q3 | -401 Thousand USD | -62.35% |
| 2022 Q1 | -259 Thousand USD | -28.86% |
| 2021 FY | -815 Thousand USD | -104.91% |
| 2021 Q1 | -218 Thousand USD | 0.0% |
| 2021 Q2 | -199 Thousand USD | 8.72% |
| 2021 Q4 | -201 Thousand USD | -2.03% |
| 2021 Q3 | -197 Thousand USD | 1.01% |
| 2020 Q2 | 6.8 Million USD | -30.45% |
| 2020 Q1 | 9.78 Million USD | 14.04% |
| 2020 Q3 | 11.4 Million USD | 67.59% |
| 2020 Q4 | - USD | -100.0% |
| 2020 FY | 16.59 Million USD | -64.77% |
| 2019 Q3 | 11.4 Million USD | -18.13% |
| 2019 Q4 | 8.58 Million USD | -24.77% |
| 2019 Q2 | 13.93 Million USD | 5.78% |
| 2019 Q1 | 13.17 Million USD | -20.79% |
| 2019 FY | 47.09 Million USD | -45.09% |
| 2018 Q1 | 26.7 Million USD | -11.59% |
| 2018 FY | 85.75 Million USD | -45.18% |
| 2018 Q2 | 25.71 Million USD | -3.68% |
| 2018 Q3 | 16.7 Million USD | -35.04% |
| 2018 Q4 | 16.62 Million USD | -0.47% |
| 2017 Q2 | 41.75 Million USD | -14.1% |
| 2017 Q1 | 48.6 Million USD | 20.03% |
| 2017 FY | 156.44 Million USD | 14.19% |
| 2017 Q4 | 30.2 Million USD | -15.84% |
| 2017 Q3 | 35.88 Million USD | -14.05% |
| 2016 Q3 | 29.24 Million USD | -16.33% |
| 2016 Q2 | 34.95 Million USD | 9.84% |
| 2016 Q1 | 31.82 Million USD | -22.24% |
| 2016 FY | 136.99 Million USD | -15.58% |
| 2016 Q4 | 40.49 Million USD | 38.47% |
| 2015 Q3 | 45.23 Million USD | -3.84% |
| 2015 Q4 | 40.92 Million USD | -9.54% |
| 2015 Q1 | 29.09 Million USD | 493.61% |
| 2015 Q2 | 47.03 Million USD | 61.67% |
| 2015 FY | 162.28 Million USD | 1324.58% |
| 2014 Q1 | 7.22 Million USD | 23.6% |
| 2014 FY | 11.39 Million USD | -37.04% |
| 2014 Q4 | -7.39 Million USD | -244.52% |
| 2014 Q2 | 6.44 Million USD | -10.76% |
| 2014 Q3 | 5.11 Million USD | -20.65% |
| 2013 Q1 | 4.14 Million USD | -28.72% |
| 2013 FY | 18.09 Million USD | -10.61% |
| 2013 Q3 | 3.84 Million USD | -9.65% |
| 2013 Q2 | 4.25 Million USD | 2.73% |
| 2013 Q4 | 5.84 Million USD | 51.91% |
| 2012 FY | 20.24 Million USD | -23.08% |
| 2012 Q4 | 5.81 Million USD | 49.18% |
| 2012 Q1 | 6.04 Million USD | -11.13% |
| 2012 Q2 | 4.48 Million USD | -25.77% |
| 2012 Q3 | 3.89 Million USD | -13.09% |
| 2011 Q3 | 9.3 Million USD | 93.09% |
| 2011 FY | 26.31 Million USD | -12.8% |
| 2011 Q4 | 6.79 Million USD | -26.93% |
| 2011 Q1 | 5.39 Million USD | -53.44% |
| 2011 Q2 | 4.81 Million USD | -10.64% |
| 2010 Q2 | 5.93 Million USD | -28.32% |
| 2010 FY | 30.18 Million USD | -5.69% |
| 2010 Q4 | 11.58 Million USD | 30.63% |
| 2010 Q1 | 8.27 Million USD | 18.5% |
| 2010 Q3 | 8.86 Million USD | 49.52% |
| 2009 Q3 | 7.33 Million USD | -4.59% |
| 2009 FY | 32 Million USD | 10.35% |
| 2009 Q4 | 6.98 Million USD | -4.77% |
| 2009 Q1 | 10 Million USD | 40.74% |
| 2009 Q2 | 7.68 Million USD | -23.19% |
| 2008 Q1 | 8.45 Million USD | 49.11% |
| 2008 Q4 | 7.1 Million USD | 8.98% |
| 2008 Q3 | 6.52 Million USD | -5.64% |
| 2008 FY | 28.99 Million USD | 49.98% |
| 2008 Q2 | 6.91 Million USD | -18.26% |
| 2007 Q4 | 5.67 Million USD | 18.94% |
| 2007 Q3 | 4.76 Million USD | 27.15% |
| 2007 Q2 | 3.75 Million USD | -27.11% |
| 2007 Q1 | 5.14 Million USD | -19.95% |
| 2007 FY | 19.33 Million USD | 15.29% |
| 2006 FY | 16.77 Million USD | -20.42% |
| 2006 Q4 | 6.42 Million USD | 80.38% |
| 2006 Q3 | 3.56 Million USD | 0.91% |
| 2006 Q2 | 3.53 Million USD | 19.53% |
| 2006 Q1 | 2.95 Million USD | -48.5% |
| 2005 Q2 | 5.23 Million USD | -32.56% |
| 2005 Q3 | 2.33 Million USD | -55.53% |
| 2005 FY | 21.07 Million USD | -59.32% |
| 2005 Q1 | 7.76 Million USD | -74.26% |
| 2005 Q4 | 5.73 Million USD | 146.18% |
| 2004 Q1 | 13.51 Million USD | 31.39% |
| 2004 Q2 | 8.11 Million USD | -39.97% |
| 2004 Q4 | 30.17 Million USD | 271.98% |
| 2004 Q3 | 8.11 Million USD | 0.0% |
| 2004 FY | 51.8 Million USD | 141.07% |
| 2003 Q2 | 4.28 Million USD | 75.56% |
| 2003 Q1 | 2.43 Million USD | 51.58% |
| 2003 Q4 | 10.28 Million USD | 129.47% |
| 2003 FY | 21.49 Million USD | 34.04% |
| 2003 Q3 | 4.48 Million USD | 4.69% |
| 2002 FY | 16.03 Million USD | 46.81% |
| 2002 Q1 | 4.56 Million USD | 0.0% |
| 2002 Q2 | 4.99 Million USD | 9.6% |
| 2002 Q3 | 5.9 Million USD | 18.02% |
| 2002 Q4 | 1.6 Million USD | -72.73% |
| 2001 Q2 | 2.43 Million USD | -29.84% |
| 2001 Q4 | 4.56 Million USD | 73.75% |
| 2001 FY | 10.92 Million USD | 19.33% |
| 2001 Q3 | 2.62 Million USD | 7.89% |
| 2001 Q1 | 3.46 Million USD | 19.5% |
| 2000 Q4 | 2.9 Million USD | -3.27% |
| 2000 Q2 | 2.84 Million USD | 43.39% |
| 2000 Q1 | 1.98 Million USD | -71.72% |
| 2000 FY | 9.15 Million USD | 2.22% |
| 2000 Q3 | 3 Million USD | 5.56% |
| 1999 FY | 8.95 Million USD | 49.49% |
| 1999 Q4 | 7 Million USD | 315.17% |
| 1999 Q3 | 1.68 Million USD | 61.38% |
| 1999 Q2 | 1.04 Million USD | -19.54% |
| 1999 Q1 | 1.3 Million USD | -55.51% |
| 1998 Q2 | 2.7 Million USD | 145.45% |
| 1998 Q3 | 1.7 Million USD | -37.04% |
| 1998 FY | 5.98 Million USD | 19.78% |
| 1998 Q4 | 2.92 Million USD | 71.88% |
| 1998 Q1 | 1.1 Million USD | -67.65% |
| 1997 Q4 | 3.4 Million USD | 183.33% |
| 1997 FY | 5 Million USD | 11.11% |
| 1997 Q1 | 2.1 Million USD | 75.0% |
| 1997 Q2 | 1.3 Million USD | -38.1% |
| 1997 Q3 | 1.2 Million USD | -7.69% |
| 1996 Q2 | 900 Thousand USD | -59.09% |
| 1996 Q1 | 2.2 Million USD | 0.0% |
| 1996 Q3 | 700 Thousand USD | -22.22% |
| 1996 Q4 | 1.2 Million USD | 71.43% |
| 1996 FY | 4.5 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 326.16 Million USD | 91.686% |
| Embecta Corp. | 749.9 Million USD | 96.384% |
| ANI Pharmaceuticals, Inc. | 305.3 Million USD | 91.118% |
| Dynavax Technologies Corporation | 182.11 Million USD | 85.11% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | 62.887% |
| Pacira BioSciences, Inc. | 490.3 Million USD | 94.469% |
| PainReform Ltd. | -15 Thousand USD | 180880.0% |
| Aquestive Therapeutics, Inc. | 29.75 Million USD | 8.857% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -225.176% |
| SCYNEXIS, Inc. | 124.51 Million USD | 78.222% |
| China SXT Pharmaceuticals, Inc. | 553.97 Thousand USD | -4795.022% |
| Cosmos Health Inc. | 4.34 Million USD | -523.441% |
| Journey Medical Corporation | 52.52 Million USD | 48.369% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -225.176% |
| Safety Shot Inc | -74.45 Thousand USD | 36519.678% |
| Alpha Teknova, Inc. | 10.29 Million USD | -163.374% |
| Intra-Cellular Therapies, Inc. | 430.62 Million USD | 93.703% |
| Bright Green Corporation | -237.01 Thousand USD | 11541.0% |
| Procaps Group, S.A. | 239.56 Million USD | 88.681% |
| Theratechnologies Inc. | 62.12 Million USD | 56.354% |
| Harrow Health, Inc. | 90.55 Million USD | 70.054% |
| Sonoma Pharmaceuticals, Inc. | 4.74 Million USD | -471.486% |
| Biofrontera Inc. | 16.62 Million USD | -63.09% |
| DURECT Corporation | 6.83 Million USD | -296.97% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 94.822% |
| Cronos Group Inc. | 6.99 Million USD | -287.89% |
| OptiNose, Inc. | 62.35 Million USD | 56.511% |
| Ironwood Pharmaceuticals, Inc. | 441.16 Million USD | 93.853% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 9049.505% |
| RedHill Biopharma Ltd. | 3.05 Million USD | -787.867% |
| Organogenesis Holdings Inc. | 309.79 Million USD | 91.247% |
| Guardion Health Sciences, Inc. | 5.39 Million USD | -402.677% |
| Cumberland Pharmaceuticals Inc. | 33.48 Million USD | 19.02% |
| Radius Health, Inc. | 307.71 Million USD | 91.188% |
| Universe Pharmaceuticals INC | 10.07 Million USD | -169.074% |
| ProPhase Labs, Inc. | 16.23 Million USD | -66.987% |
| Phibro Animal Health Corporation | 312.48 Million USD | 91.322% |
| Procaps Group S.A. | 239.56 Million USD | 88.681% |
| Alvotech | -69.42 Million USD | 139.061% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -1982.719% |
| Viatris Inc. | 6.43 Billion USD | 99.579% |
| Rockwell Medical, Inc. | 8.7 Million USD | -211.546% |
| Aytu BioPharma, Inc. | 54.58 Million USD | 50.322% |
| SIGA Technologies, Inc. | 122.09 Million USD | 77.79% |
| Tilray Brands, Inc. | 223.35 Million USD | 87.859% |
| Lifecore Biomedical, Inc. | 41.85 Million USD | 35.204% |
| Shineco, Inc. | 882.16 Thousand USD | -2973.904% |
| PetIQ, Inc. | 252.74 Million USD | 89.271% |
| Regencell Bioscience Holdings Limited | -745.58 Thousand USD | 3736.995% |
| Incannex Healthcare Limited | 12 Thousand USD | -225875.0% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 98.532% |
| Alimera Sciences, Inc. | 61.17 Million USD | 55.669% |
| Silver Spike Investment Corp. | 8.1 Million USD | -234.67% |
| Assertio Holdings, Inc. | 125.04 Million USD | 78.315% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6811.00 USD | 398235.369% |
| Petros Pharmaceuticals, Inc. | 4.19 Million USD | -547.003% |
| Clever Leaves Holdings Inc. | 6.55 Million USD | -313.621% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 1225.105% |
| Hempacco Co., Inc. | -1.21 Million USD | 2330.323% |
| Talphera, Inc. | -4.89 Million USD | 653.973% |
| Alvotech | -69.42 Million USD | 139.061% |
| Eagle Pharmaceuticals, Inc. | 221.67 Million USD | 87.767% |
| Lantheus Holdings, Inc. | 709.54 Million USD | 96.178% |
| Currenc Group, Inc. | 17.35 Million USD | -56.237% |
| Kamada Ltd. | 52.59 Million USD | 48.44% |
| Indivior PLC | 907 Million USD | 97.01% |
| Evoke Pharma, Inc. | 4.97 Million USD | -444.655% |
| Flora Growth Corp. | 17.73 Million USD | -52.875% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 1225.105% |
| Evolus, Inc. | 140.52 Million USD | 80.703% |
| HUTCHMED (China) Limited | 453.55 Million USD | 94.021% |
| Amphastar Pharmaceuticals, Inc. | 343.96 Million USD | 92.116% |
| Akanda Corp. | 111.44 Thousand USD | -24231.308% |